These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25901930)

  • 1. Comparison between recombinant human parathyroid hormone (1-34) and elcatonin in treatment of primary osteoporosis.
    Yang Y; Zhang XJ; Zhu XJ; Zhang L; Bao MJ; Xian Y; Wu JC; Liu LM; Li PQ
    Asian Pac J Trop Med; 2015 Jan; 8(1):79-84. PubMed ID: 25901930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y; Xuan M; Wang B; Yang J; Zhang H; Zhang XZ; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Liu ZM; Li CJ; Wu TF; Sheng ZY; Li PQ; Tong JC
    Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China].
    Zhang XZ; Song LG; Wang B; Yang J; Li H; Xuan M; Lei T; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Shen J; Liu ZM; Li CJ; Wu TF; Xie HB; Tong JC
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):662-6. PubMed ID: 20979784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ; Wang B; Yang J; Xuan M; Song LG; Li H; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Shen J; Liu ZM; Li CJ; Wu TF; Tong XC; Jia Y
    Chin Med J (Engl); 2009 Dec; 122(24):2933-8. PubMed ID: 20137477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.
    Zhang L; Yang M; Liu D; Guo C; Li L; Yang G
    Exp Clin Endocrinol Diabetes; 2012 Jun; 120(6):361-6. PubMed ID: 22639400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis.
    Zhang L; Li L; Yang M; Xu K; Boden G; Yang G
    Osteoporos Int; 2013 Mar; 24(3):1107-12. PubMed ID: 22419369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
    Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
    Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
    Zanchetta JR; Bogado CE; Cisari C; Aslanidis S; Greisen H; Fox J; Lems W
    Curr Med Res Opin; 2010 Nov; 26(11):2627-33. PubMed ID: 20923256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX; Li H
    Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
    J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of salmon calcitonin in treatment of osteoporosis in patients undergoing dialysis].
    Wang SX; Li H
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):387-90. PubMed ID: 18581891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model.
    Chou FF; Huang SC; Chen SS; Wang PW; Huang PH; Lu KY
    Osteoporos Int; 2006; 17(6):936-41. PubMed ID: 16596462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.